Supernus Pharmaceuticals to Release Q1 2025 Results

By Tamara Parker • Thursday, April 24 06:06 • Permanent Link

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) has announced that it will be releasing its financial and business results for the first quarter of 2025 after the market closes on Tuesday, May 6, 2025.

In the previous period, Supernus Pharmaceuticals reported a total revenue of $166.7 million, reflecting a 22% increase compared to the same period in the prior year. The net product sales were $163.6 million, a 23% increase from the previous year. The company's Research and Development expenses were $27.5 million, representing a 14% increase from the same period in the prior year. Additionally, the Selling, General, and Administrative expenses were $45.1 million, showing a 3% decrease from the previous year.

During the first quarter of 2025, Supernus Pharmaceuticals expects to provide further details of its financial and business performance. The company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Supernus Pharmaceuticals is also developing a broad range of novel CNS product candidates, including new potential treatments for epilepsy, depression, and other CNS disorders.

The company will be hosting a conference call on Tuesday, May 6, 2025, at 4:30 p.m. ET to present the first quarter 2025 financial and business results. This will provide an opportunity for analysts, investors, and the media to delve into the specifics of the company's performance and pose questions to the management team.

Following the live call, a replay will be available on the company's investor relations website for those who may have missed the initial presentation. Moreover, a live webcast will be accessible in the events & presentations section of the company’s investor relations website for those unable to attend the conference call.

As the release date approaches, market analysts and investors will be eagerly awaiting the specifics of Supernus Pharmaceuticals' financial and business performance for the first quarter of 2025, looking for indications of the company's trajectory and future prospects. Today the company's shares have moved 0.0% to a price of $30.84. For the full picture, make sure to review Supernus Pharmaceuticals's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.